This company has been marked as potentially delisted and may not be actively trading. Gritstone bio (GRTS) FDA Approvals Add Compare Share Share FDA Events Stock AnalysisFDA EventsInsider TradesTrendsBuy This Stock Gritstone bio's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Gritstone bio (GRTS). Over the past two years, Gritstone bio has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as GRANITE. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. GRANITE (GRT-C901/GRT-R902) FDA Regulatory Events GRANITE (GRT-C901/GRT-R902) is a drug developed by Gritstone bio for the following indication: In frontline microsatellite stable colorectal cancer. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Survival data - September 30,2024Survival Data Drug: GRANITE (GRT-C901/GRT-R902)Announced Date: September 30, 2024Target Action Date: H2 2025Estimated Target Date Range: July 1, 2025 - December 31, 2025Indication: In frontline microsatellite stable colorectal cancerAnnouncementGritstone bio, Inc announced Overall survival data expected in 2H 2025AI SummaryGritstone bio, Inc. recently shared encouraging interim Phase 2 data from its study evaluating GRANITE, an individualized neoantigen targeting immunotherapy for frontline microsatellite stable colorectal cancer. The trial compared GRANITE in combination with immune checkpoint inhibitors, fluoropyrimidine, and bevacizumab to standard treatment. Early results show a reduction in the risk of progression or death, with a 21% overall relative risk reduction and a 38% reduction for patients with lower disease burden as measured by ctDNA. The company emphasized that the treatment was well-tolerated, with patients maintaining stable ctDNA levels and no treatment discontinuations due to side effects. Importantly, Gritstone bio announced that overall survival data from the study are expected in the second half of 2025. Further follow-up is needed to confirm and mature these promising findings.Read AnnouncementInterim Data - September 30,2024Interim Data Phase 2Drug: GRANITE (GRT-C901/GRT-R902)Announced Date: September 30, 2024Indication: In frontline microsatellite stable colorectal cancerAnnouncementGritstone bio, Inc. announced encouraging interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen targeting immunotherapy, in frontline microsatellite stable colorectal cancer (MSS-CRC).AI SummaryGritstone bio, Inc. announced encouraging interim Phase 2 data for GRANITE, its individualized neoantigen targeting immunotherapy, in frontline microsatellite stable colorectal cancer (MSS-CRC). The study compared patients receiving GRANITE plus immune checkpoint inhibitors and other standard treatments against those receiving standard care alone. Overall, patients treated with GRANITE experienced a 21% relative risk reduction in progression or death. Notably, patients with a lower disease burden—indicated by low ctDNA levels at the start of the study—showed a 38% relative risk reduction. The results also showed that stronger neoantigen-specific T cell responses were linked to improved progression-free survival. GRANITE was generally well-tolerated, with no patients discontinuing treatment due to adverse events. Further follow-up is needed to confirm these findings, and overall survival data are expected in the second half of 2025.Read Announcement Gritstone bio FDA Events - Frequently Asked Questions Has Gritstone bio received FDA approval? As of now, Gritstone bio (GRTS) has not received any FDA approvals for its therapy in the last two years. What drugs has Gritstone bio submitted to the FDA? In the past two years, Gritstone bio (GRTS) has reported FDA regulatory activity for GRANITE (GRT-C901/GRT-R902). What is the most recent FDA event for Gritstone bio? The most recent FDA-related event for Gritstone bio occurred on September 30, 2024, involving GRANITE (GRT-C901/GRT-R902). The update was categorized as "Survival data," with the company reporting: "Gritstone bio, Inc announced Overall survival data expected in 2H 2025" What conditions do Gritstone bio's current drugs treat? Currently, Gritstone bio has one therapy (GRANITE (GRT-C901/GRT-R902)) targeting the following condition: In frontline microsatellite stable colorectal cancer. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Axsome Therapeutics FDA EventsBiogen FDA EventsFate Therapeutics FDA EventsGH Research FDA EventsIncyte FDA EventsJazz Pharmaceuticals FDA EventsMoleculin Biotech FDA EventsMirum Pharmaceuticals FDA EventsNextCure FDA EventsPharming Group FDA EventsRegeneron Pharmaceuticals FDA Eventsargenex FDA EventsCabaletta Bio FDA EventsDyne Therapeutics FDA EventsFibroBiologics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies BioLineRx FDA Events CytoMed Therapeutics FDA Events Ernexa Therapeutics FDA Events Moleculin Biotech FDA Events Phio Pharmaceuticals FDA Events GeoVax Labs FDA Events LianBio FDA Events Aprea Therapeutics FDA Events BioVie FDA Events BioCardia FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:GRTS last updated on 6/20/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersDo NOT Buy SpaceX – Do This InsteadSpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredElon’s big June 12 announcementJune 12 is the reported deadline for a major announcement tied to Elon Musk's so-called 'Project Unlimited' - ...Weiss Ratings | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gritstone bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gritstone bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Survival data - September 30,2024Survival Data Drug: GRANITE (GRT-C901/GRT-R902)Announced Date: September 30, 2024Target Action Date: H2 2025Estimated Target Date Range: July 1, 2025 - December 31, 2025Indication: In frontline microsatellite stable colorectal cancerAnnouncementGritstone bio, Inc announced Overall survival data expected in 2H 2025AI SummaryGritstone bio, Inc. recently shared encouraging interim Phase 2 data from its study evaluating GRANITE, an individualized neoantigen targeting immunotherapy for frontline microsatellite stable colorectal cancer. The trial compared GRANITE in combination with immune checkpoint inhibitors, fluoropyrimidine, and bevacizumab to standard treatment. Early results show a reduction in the risk of progression or death, with a 21% overall relative risk reduction and a 38% reduction for patients with lower disease burden as measured by ctDNA. The company emphasized that the treatment was well-tolerated, with patients maintaining stable ctDNA levels and no treatment discontinuations due to side effects. Importantly, Gritstone bio announced that overall survival data from the study are expected in the second half of 2025. Further follow-up is needed to confirm and mature these promising findings.Read Announcement
Interim Data - September 30,2024Interim Data Phase 2Drug: GRANITE (GRT-C901/GRT-R902)Announced Date: September 30, 2024Indication: In frontline microsatellite stable colorectal cancerAnnouncementGritstone bio, Inc. announced encouraging interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen targeting immunotherapy, in frontline microsatellite stable colorectal cancer (MSS-CRC).AI SummaryGritstone bio, Inc. announced encouraging interim Phase 2 data for GRANITE, its individualized neoantigen targeting immunotherapy, in frontline microsatellite stable colorectal cancer (MSS-CRC). The study compared patients receiving GRANITE plus immune checkpoint inhibitors and other standard treatments against those receiving standard care alone. Overall, patients treated with GRANITE experienced a 21% relative risk reduction in progression or death. Notably, patients with a lower disease burden—indicated by low ctDNA levels at the start of the study—showed a 38% relative risk reduction. The results also showed that stronger neoantigen-specific T cell responses were linked to improved progression-free survival. GRANITE was generally well-tolerated, with no patients discontinuing treatment due to adverse events. Further follow-up is needed to confirm these findings, and overall survival data are expected in the second half of 2025.Read Announcement
